Intradermal immunization improves protective efficacy of a novel TB vaccine candidate
Intradermal immunization improves protective efficacy of a novel TB vaccine candidate
复制标题
DOI：
10.1016/j.vaccine.2009.03.018
复制
发表时间：
2009-05-18
期刊：
影响因子：
5.5
通讯作者：
Coler, Rhea N.
中科院分区：
文献类型：
--
作者：
Baldwin, Susan L.;Bertholet, Sylvie;Coler, Rhea N.
我们开发了结核分枝杆菌 (Mtb) 融合蛋白 (11383)，其中包含三种 Mtb 蛋白 Rv1813、Rv3620 和 Rv2608。我们评估了 ID83 与几种乳液配制的 Toll 样受体激动剂组合的免疫原性和保护功效。含有合成 TLR4 或 TLR9 激动剂的 ID83 亚单位疫苗可产生 T 辅助细胞 1 免疫反应，并保护小鼠免受 Mtb 的攻击，无论途径如何。用加迪喹莫特（一种 TLR7 激动剂）配制的 ID83 疫苗在皮内注射时也能产生保护性反应，而皮下注射的相同疫苗则无法提供保护。这突出表明需要根据所使用的佐剂制剂探索不同的免疫途径。 (C) 2009 Elsevier Ltd. 保留所有权利。
We have developed the Mycobacterium tuberculosis (Mtb) fusion protein (11383), which contains the three Mtb proteins Rv1813, Rv3620 and Rv2608. We evaluated the immunogenicity and protective efficacy of ID83 in combination with several emulsion-formulated toll-like receptor agonists. The ID83 subunit vaccines containing synthetic TLR4 or TLR9 agonists generated a T helper-1 immune response and protected mice against challenge with Mtb regardless of route. The ID83 vaccine formulated with gardiquimod (a TLR7 agonist) also resulted in a protective response when administered intradermally, whereas the same vaccine given subcutaneously failed to provide protection. This highlights the need to explore different routes of immunization based on the adjuvant formulations used. (C) 2009 Elsevier Ltd. All rights reserved.